MetaCap

Akebia Therapeutics Inc. (AKBA)

NASDAQ: AKBAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.3855-0.0368 (-8.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AKBA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$107.04M
EPS (TTM)
-$0.17
52-week range
0.361 – 1.73
Day range
0.3849 – 0.4331
Volume / Avg
4.57M / 8.05M
Beta
—

52-week range

$0.361$1.73

AKBA stock today

Shares of Akebia Therapeutics (AKBA) finished lower on Nov 20 at $0.3855, a drop of 8.71% or $0.0368 per share, versus the S&P 500's 3.70% decline. Shares are 77.7% below their 52-week high of $1.73, set on Dec 22, 2025 and 6.8% above the 52-week low of $0.361, near the bottom of the past year's range. AKBA is down 76.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.1%.

Akebia Therapeutics has posted a net loss over the last twelve months (EPS of -$0.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Akebia Therapeutics

Company profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. John P. Butler MBA
Headquarters
Waltham, MA
Employees
194
IPO year
2014
Website
akebia.com

Financial highlights

Full financials

In fiscal 2025, Akebia Therapeutics generated $236.2 million in revenue, up 47.5% from fiscal 2024. Akebia Therapeutics reported a net loss of $5.3 million, compared with a loss of $69.4 million a year earlier. Gross margin was 83.3% (up from 60.6%) and operating margin 9.9%.

Akebia Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$236.20M$160.18M$194.62M$292.48M$211.65M
Growth+47.46%-17.70%-33.46%+38.19%-28.17%
Net income$-5.34M$-69.41M$-51.92M$-94.23M$-282.02M
EPS (diluted)$-0.02$-0.33$-0.28$-0.52$-1.70

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$3.00+678.21%

  • Strong buy 1
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $4.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.05 vs $-0.03
Surprise
-66.67%

AKBA news

All AKBA news

Akebia Therapeutics peers

Health Care sector
AKBA peer companies
CompanyPrice% ChgMarket capCompare
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs AKBA
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs AKBA
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs AKBA
GNLXGenelux Corporation2.17-4.82%$103.36Mvs AKBA
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs AKBA
IMUXImmunic Inc.6.99-5.41%$111.01Mvs AKBA
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs AKBA
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs AKBA

Indexes, lists and sector

Akebia Therapeutics stock FAQ

What is Akebia Therapeutics's stock price today?

AKBA last traded at $0.3855 as of Nov 20, 4:00 PM EST, down 8.71% on the day. Prices are delayed at least 15 minutes.

Who is Akebia Therapeutics's CEO?

Mr. John P. Butler MBA is the chief executive officer of Akebia Therapeutics Inc., which has about 194 employees.

What is the AKBA 52-week high?

The 52-week high for AKBA is $1.73 and the 52-week low is $0.361. The stock is currently 77.7% below its high.

Compare AKBA